AstraZeneca announced the appointment of Iskra Reic as Executive Vice President (EVP), International, effective immediately. Reic will oversee the company’s strategy and growth across the vast International region, including markets in China, Asia, Eurasia, the Middle East & Africa, Latin America, and Australia & New Zealand.
Having been with AstraZeneca since 2001, Iskra Reic has held various leadership positions in different regions, including Central & Eastern Europe, Eurasia, the Middle East & Africa. She was appointed EVP for Europe & Canada in 2017 and became a member of AstraZeneca’s Senior Executive Team. Reic’s most recent role was as EVP of the Vaccines & Immune Therapies unit, where she successfully spearheaded the company’s efforts in developing and launching key vaccines and monoclonal antibodies. These included products for COVID-19 and respiratory syncytial virus (RSV), along with driving strategic partnerships and acquisitions within the unit.
Pascal Soriot, CEO of AstraZeneca, expressed confidence in Reic’s leadership, highlighting her extensive international experience and a strong track record in improving patient access to AstraZeneca’s innovative treatments. He further emphasized that her ability to build partnerships will be key to driving growth in AstraZeneca’s rapidly expanding international markets.
Iskra Reic, on her new appointment, expressed excitement about leading such a diverse and innovative region. She stated, “It is a privilege to lead this broad, diverse, and innovative region as we deliver the next wave of science and innovative medicines. I look forward to working with our partners, stakeholders, and colleagues to improve the lives of millions of people around the world with our leading medicines and vaccines.”
Reic succeeds Leon Wang, who is on extended leave from the company while under investigation in China.
Biography of Iskra Reic
Iskra Reic’s career at AstraZeneca spans over two decades. She first joined the company in 2001, advancing through various leadership roles, including EVP for Europe & Canada, and more recently, EVP of Vaccines & Immune Therapies. Reic has also played key roles in Central & Eastern Europe, Eurasia, the Middle East, and Africa, with responsibility for driving AstraZeneca’s commercial operations and strategic goals in those regions. Since 2017, she has been a member of the company’s Senior Executive Team.
In her most recent role as EVP of Vaccines & Immune Therapies, Reic oversaw both early and late-stage development of a pipeline that includes vaccines for COVID-19, RSV, and other monoclonal antibodies. Her role also involved strategic acquisitions, partnerships, and the commercial success of the unit’s products.
Reic holds a PhD and an MBA in Business and Leadership from the IEDC-Bled School of Management in Slovenia. She also holds a DMD from the Medical University of Zagreb. Beyond her work at AstraZeneca, she is a member of the Board of Directors at myTomorrows, a global health technology company. Additionally, she is part of the Steering Committee for the Partnership for Health System Sustainability and Resilience, an initiative focused on improving patient outcomes worldwide.
Source Link
